Zimmer Biomet Holdings, Inc. (ZBH)

Market Cap	19.24B
Revenue (ttm)	8.01B
Net Income (ttm)	805.30M
Shares Out	198.21M
EPS (ttm)	4.03
PE Ratio	24.07
Forward PE	11.55
Dividend	$0.96 (0.99%)
Ex-Dividend Date	Sep 30, 2025

Volume	1,856,299
Open	94.11
Previous Close	93.52
Day's Range	94.11 - 97.18
52-Week Range	85.33 - 114.44
Beta	0.61
Analysts	Buy
Price Target	108.56 (+11.84%)
Earnings Date	Nov 5, 2025

About ZBH

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open hear...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1927
• Employees: 17,000
• Stock Exchange: NYSE
• Ticker Symbol: ZBH
• Website: https://www.zimmerbiomet.com

Financial Performance

In 2024, Zimmer Biomet Holdings's revenue was $7.68 billion, an increase of 3.85% compared to the previous year's $7.39 billion. Earnings were $903.80 million, a decrease of -11.74%.

Analyst Summary

According to 19 analysts, the average rating for ZBH stock is "Buy." The 12-month stock price target is $108.56, which is an increase of 11.84% from the latest price.

Price Target

$108.56

(11.84% upside)

Analyst Consensus: Buy